ETI104

antigen-heteropolymer for treatment of patients with systemic lupus erythematosus; ETI-104 is a murine anti-complement receptor I monoclonal antibody (7G9) of IgG2a sublclass conjugated to dsDNA derived from salmon testis

Also Known As:

ETI-104

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Bleck, E: 1 article (09/2004)
2.	Engelbrecht, R: 1 article (09/2004)
3.	Fischer-Betz, R: 1 article (09/2004)
4.	Iking-Konert, C: 1 article (09/2004)
5.	Nardone, L: 1 article (09/2004)
6.	Perniok, A: 1 article (09/2004)
7.	Pincus, S: 1 article (09/2004)
8.	Schneider, M: 1 article (09/2004)
9.	Stocks, S: 1 article (09/2004)
10.	Weinsberg, F: 1 article (09/2004)

Related Diseases

Systemic Lupus Erythematosus (Libman-Sacks Disease)

09/01/2004 - "To evaluate the safety and tolerability of a single administration and to establish proof of principle for ETI-104 in normal healthy volunteers (NHV) and patients with systemic lupus erythematosus (SLE) METHODS: The drug was given intravenously to 11 NHV and six patients with SLE. "
09/01/2004 - "First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104."

Related Drugs and Biologics

1.	Antigens